Senior Director, New Ventures
Johnson & Johnson Innovation Asia Pacific Innovation Center
Why I'm a JPAL
I am interested in getting to know more about the external innovation ecosystem, interacting with external entrepreneurs and start-ups, sharing my expertise and experience to help accelerate their research and development, foster potential collaborations with J&J on transformational science and technology in healthcare.
Han Dai is Senior Director, New Ventures, Johnson & Johnson Innovation Asia Pacific. Han is responsible for developing and implementing Innovation strategies in China, creating a deep and credible network with innovators and entrepreneurs in biotech, VC community, as well as leading scientists and clinicians in academia, healthcare industry and non-profit organizations. Han also focuses on the identification and evaluation of external opportunities in China, supporting negotiations and playing a critical role in management of academic and industrial collaborations that have potential to impact J&J portfolio for the global markets. Previously, Han was Executive Director at BeiGene, responsible for building innovative drug discovery platform, identifying & validating novel targets, supporting search & evaluation and due diligence. Prior to that, he held multiple roles with increasing responsibilities as Scientific Leader and GSK Fellow of Protein Degradation DPU/Future Pipeline Discovery team at GlaxoSmithKline US headquarter. At GSK, he successfully led or co-led the discovery, preclinical development, translational research and biomarker studies across many therapeutic areas, including oncology, immunology, metabolic and other diseases. Han has ~20 years’ experience in Pharma/Biotech industry with track records of successful leadership in small molecule & biologics drug discovery & development and high-profile publications. Han received his Ph.D. in Molecular Biophysics from UT Southwestern Medical Center as Frank and Sara McKnight fellow, and his B.S. in Biochemistry from Department for Intensive Instruction, Nanjing University. Han completed his postdoctoral training in Harvard Medical School and HHMI as Helen Hay Whitney fellow. He has published more than 40 papers, book chapters, abstracts and patents in reputable journals and conferences. Han served as Scientific Advisory Board member of the Chemical Probes Portal, Full Faculty Member of F1000 Drug Discovery & Design Section, President of Sino-American Pharmaceutical Professional Association – Greater Philadelphia (SAPA-GP) and VP of SAPA-HQ as well as a visiting professor at High Magnetic Field Laboratory of the Chinese Academy of Sciences (CHMFL).
“There is so much more to be done; the patients are waiting.”
- Dr. Paul Janssen
Have a hobby to visualize molecules